Apimeds Pharmaceuticals US, Inc. (APUS) - Total Assets
Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) holds total assets worth $141.22 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Apimeds Pharmaceuticals US, Inc. - Total Assets Trend (2021–2025)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see market cap of Apimeds Pharmaceuticals US, Inc. for the company's overall valuation and market capitalisation.
Apimeds Pharmaceuticals US, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Apimeds Pharmaceuticals US, Inc.'s total assets of $141.22 Million consist of 8.5% current assets and 91.5% non-current assets. Review Apimeds Pharmaceuticals US, Inc. (APUS) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See APUS live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apimeds Pharmaceuticals US, Inc.'s current assets represent 8.5% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2025, down from 99.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Apimeds Pharmaceuticals US, Inc. Competitors by Total Assets
Key competitors of Apimeds Pharmaceuticals US, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Apimeds Pharmaceuticals US, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 0.15 | 0.02 |
| Quick Ratio | 0.90 | 0.15 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.43 Million | $-1.51 Million | $-313.61K |
Apimeds Pharmaceuticals US, Inc. - Advanced Valuation Insights
This section examines the relationship between Apimeds Pharmaceuticals US, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.05 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 1257338.4% |
| Total Assets | $164.18 Million |
| Market Capitalization | $2.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Apimeds Pharmaceuticals US, Inc.'s assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Apimeds Pharmaceuticals US, Inc.'s assets grew by 1257338.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Apimeds Pharmaceuticals US, Inc. (2021–2025)
The table below shows the annual total assets of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $164.18 Million | +1257338.43% |
| 2024-12-31 | $13.06K | -96.91% |
| 2023-12-31 | $422.08K | +6739.67% |
| 2022-12-31 | $6.17K | -96.42% |
| 2021-12-31 | $172.17K | -- |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.